开立医疗 (300633)

SONOSCAPE MEDICAL CORP.

ASZ

Tags

Special Purpose Equipment ManufacturingChina-Russia TradeMedical DevicesPharmaceuticals and HealthcareGuozheng Growth IndexPet EconomySmall Cap GrowthMargin Trading and Securities LendingChiNext 200 IndexChiNext 300 IndexChiNext InnovationChiNext HealthcareChiNext TechSZSE Innovation Index

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 43271.24
  • Circulating A-Shares(W): 43271.24
  • Earnings Per Share(RMB): 0.0774
  • Net Assets Per Share(RMB): 7.2084
  • Operating Revenue(W RMB): 145931.12
  • Total Profit(W RMB): 895.73
  • Net Profit Attributable to Parent(W RMB): 3351.11
  • Net Profit Growth Rate(%): -69.25
  • Weighted Return on Equity(%): 1.07
  • Operating Cash Flow Per Share(RMB): -0.8800
  • Undistributed Profit Per Share(RMB): 3.2434
  • Capital Reserve Per Share(RMB): 2.6647

2. Main Business

The main business covers:

  • Research, development, production and sales of medical diagnostic and therapeutic equipment.

3. Company Basic Information

  • Company Name: Shenzhen Sonoscape Medical Corp.
  • Listing Date: 2017-04-06
  • Industry: Special Purpose Equipment Manufacturing (Tongdaxin Research Industry: Medicine & Medical - Medical Devices)
  • Address: Sonoscape Medical Building, No. 368 Guangdian North Road, Guangming District, Shenzhen, Guangdong, China
  • Website: www.sonoscape.com
  • Company Profile: The Company was established through the overall change of Sonoscape Co., Ltd. into a joint stock company. The predecessor, Sonoscape Co., Ltd., was founded on September 27, 2002, led by Mr. Yao Jinzhong. Mr. Yao Jinzhong is one of the pioneers and founders of China's ultrasonic instrument industry. He has been engaged in the research, development, and manufacturing of ultrasonic instruments since the 1960s, serving as the director of Shantou Ultrasonic Instrument Research Institute, deputy general manager, and chief engineer of Shantou Ultrasonic Electronic Instrument Company. In 1995, he was awarded as an outstanding top talent and municipal expert in Shantou City. He was a representative of the 5th, 6th, and 7th National People's Congress, a national-level "Young and Middle-aged Expert with Outstanding Contributions," and one of the first experts to receive the State Council Special Allowance. On December 20, 2014, all shareholders of Sonoscape Co., Ltd. signed the "Shareholders' Meeting Resolution," agreeing to use the original shareholders of Sonoscape Co., Ltd. as the promoters of the joint stock company, and to convert the audited net asset value of RMB 464,400,023.34 as of October 31, 2014 into a total share capital of 360 million shares. After the conversion, the total share capital of the joint stock company was RMB 360 million, and the excess portion of net assets, RMB 104,400,023.34, was included in the company's capital reserve. Tianjian Certified Public Accountants issued the Tianjian Yan [2014] 3-92 "Capital Verification Report" regarding the establishment of the joint stock company. On December 31, 2014, Sonoscape Medical obtained the "Business License" with registration number 440301103617854 issued by the Shenzhen Market Supervision Administration.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 ChinaAMC Fund Management Co., Ltd. - Social Security Fund 17022 Portfolio Social Security Fund 843.58 1.95
2 Hong Kong Securities Clearing Company Ltd. Northbound Capital 740.04 1.71
3 HuaBao CSI Medical ETF Fund 611.94 1.41
4 Rongtong Health Industry Flexible Allocation Hybrid Securities Investment Fund Class A Fund 560.00 1.29
5 Penghua Fund - China Life Insurance Company Limited - Participating Insurance - Penghua Fund China Life Shares Growth Equity Portfolio Single Asset Management Plan (Available for Sale) Asset Management Plan 549.23 1.27
6 Rongtong China Wind No.1 Flexible Allocation Hybrid Securities Investment Fund Class A Fund 180.00 0.42
7 GF Balanced Growth Hybrid Securities Investment Fund Class A Fund 150.00 0.35
8 Rongtong Xinxin Growth Hybrid Securities Investment Fund Class A Fund 150.00 0.35
9 GF Theme Leading Flexible Allocation Hybrid Securities Investment Fund Class A Fund 147.00 0.34
10 GF Tongyuan Return Hybrid Securities Investment Fund Class A Fund 130.00 0.30

5. Concept Sectors

  • China-Russia Trade
  • Pet Economy
  • Margin Trading & Securities Lending
  • Small-Cap Growth
  • SZSE Growth Index
  • ChiNext 300
  • SZSE Innovation Index
  • ChiNext Innovation
  • ChiNext Technology
  • ChiNext Medicine
  • ChiNext 200

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information